1. Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications.
- Author
-
Al-Nesf MAY, Abdesselem HB, Bensmail I, Ibrahim S, Saeed WAH, Mohammed SSI, Razok A, Alhussain H, Aly RMA, Al Maslamani M, Ouararhni K, Khatib MY, Hssain AA, Omrani AS, Al-Kaabi S, Al Khal A, Al-Thani AA, Samsam W, Farooq A, Al-Suwaidi J, Al-Maadheed M, Al-Siddiqi HH, Butler AE, Decock JV, Mohamed-Ali V, and Al-Ejeh F
- Subjects
- Adult, Cytokines blood, Female, Humans, Male, Middle Aged, Prognosis, Proteomics methods, SARS-CoV-2 drug effects, Young Adult, COVID-19 Drug Treatment, Blood Proteins analysis, COVID-19 mortality, COVID-19 pathology, Severity of Illness Index
- Abstract
COVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF